Holen Sie sich die Stockscreener-App
13.50
3.11%
-0.4471
Schlusskurs vom Vortag:
$13.95
Offen:
$14.07
24-Stunden-Volumen:
268.69K
Relative Volume:
1.58
Marktkapitalisierung:
$394.59M
Einnahmen:
$69.21M
Nettoeinkommen (Verlust:
$-61.98M
KGV:
-5.204
EPS:
-2.5947
Netto-Cashflow:
$-18.46M
1W Leistung:
-1.77%
1M Leistung:
+1.55%
6M Leistung:
-3.04%
1J Leistung:
+132.64%
1-Tages-Spanne:
$13.38
$14.11
1-Wochen-Bereich:
$13.38
$14.40
52-Wochen-Spanne:
$5.70
$17.15
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
Firmenname
Enanta Pharmaceuticals Inc
Sektor
Branche
Telefon
617 607 0800
Adresse
4 KINGSBURY AVENUE, WATERTOWN, MA
Compare ENTA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
13.57 | 405.64M | 69.21M | -61.98M | -18.46M | -2.5947 |
VRTX
Vertex Pharmaceuticals Inc
|
436.73 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.57 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
805.44 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.70 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.28 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-26 | Eingeleitet | Rodman & Renshaw | Buy |
| 2025-11-14 | Eingeleitet | JP Morgan | Overweight |
| 2025-10-01 | Hochstufung | Jefferies | Hold → Buy |
| 2025-07-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2023-08-09 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-08-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-12-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-06-01 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-09-09 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-11-24 | Eingeleitet | Evercore ISI | Underperform |
| 2020-08-28 | Fortgesetzt | ROTH Capital | Buy |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-27 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-05-24 | Eingeleitet | Wolfe Research | Outperform |
| 2019-04-23 | Hochstufung | Berenberg | Hold → Buy |
| 2018-12-13 | Eingeleitet | Berenberg | Hold |
| 2018-06-06 | Eingeleitet | ROTH Capital | Buy |
| 2018-02-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-07-11 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Bestätigt | Barclays | Underweight |
| 2015-10-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2015-10-23 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
Alle ansehen
Enanta Pharmaceuticals Inc Aktie (ENTA) Neueste Nachrichten
Discipline and Rules-Based Execution in ENTA Response - Stock Traders Daily
Enanta Pharma's RSV Bet And Immunology Ambitions - RTTNews
Enanta Pharmaceuticals (ENTA) Q2 Loss Improvement Tests Bearish Profitability Narratives - Sahm
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - simplywall.st
Enanta Pharmaceuticals Q2 2026 Financial Results and Management Discussion – 10-Q Report Highlights - Minichart
ENANTA PHARMACEUTICALS INC 3Q 2026: Revenue $17.16M, EPS $(0.45) — 10-Q Summary - TradingView
Enanta Pharmaceuticals (NASDAQ: ENTA) trims losses on higher HCV royalties and lower R&D - Stock Titan
Number of shareholders of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView
Enanta Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
ENTA Stock Price, Quote & Chart | ENANTA PHARMACEUTICALS INC (NASDAQ:ENTA) - ChartMill
Enanta (ENTA) Reports Strong Q2 Revenue and Progress in Clinical Trials - GuruFocus
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates - sharewise.com
Is Enanta Pharmaceuticals (ENTA) Overvalued After Q2 FY26 Beat? - GuruFocus
ENANTA PHARMACEUTICALS INC (NASDAQ:ENTA) Q2 Results: Narrower Losses, Clinical Milestones in Focus - ChartMill
ENANTA PHARMACEUTICALS ($ENTA) Releases Q2 2026 Earnings - Quiver Quantitative
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026 - Weekly Voice
Enanta Pharma Q2 loss narrows on higher AbbVie royalties, lower costs - TradingView
Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot - marketscreener.com
[8-K] ENANTA PHARMACEUTICALS INC Reports Material Event - Stock Titan
MSN Money - MSN
Enanta Pharmaceuticals Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
Behavioral Patterns of ENTA and Institutional Flows - Stock Traders Daily
Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last? - Yahoo Finance
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Progr - PharmiWeb.com
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026 - BioSpace
Enanta rises as J.P. Morgan starts at Overweight on RSV therapy - MSN
(ENTA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
ENTA Price Today: Enanta Pharmaceuticals, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
ENTA (Enanta Pharmaceuticals Inc.) posts 49 percent narrower Q1 2026 loss than expected, shares fall 3.37 percent on slight revenue decline.Management Guidance - Xã Thanh Hà
How (ENTA) Movements Inform Risk Allocation Models - Stock Traders Daily
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Above 50-Day Moving AverageHere's Why - MarketBeat
Enanta (ENTA) Begins Phase 1 Trial for EDP-978 - GuruFocus
Enanta doses first patient in phase 1 trial of urticaria drug - Investing.com Australia
Gains Report: Should I trade or invest in Enanta Pharmaceuticals IncEarnings Summary Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria - BioSpace
Enanta Pharmaceuticals Initiates Phase 1 Trial of EDP-978 in Chronic Urticaria - marketscreener.com
Enanta doses first patient in phase 1 trial of urticaria drug By Investing.com - Investing.com South Africa
Meme Stocks: Does Enanta Pharmaceuticals Inc have strong fundamentals2026 Big Picture & Weekly Setup with High ROI Potential - baoquankhu1.vn
Are investors bullish on Enanta Pharmaceuticals (ENTA) Stock | ENTA Q4 Earnings: Beats Estimates by $0.40 - Newser
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in - PharmiWeb.com
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026 - Business Wire
Is Enanta Pharmaceuticals (ENTA) Stock Suitable for 2026 | Price at $13.18, Up 0.27%Size Factor - Newser
Trading Systems Reacting to (ENTA) Volatility - Stock Traders Daily
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) Shares Pass Below 200 Day Moving AverageShould You Sell? - MarketBeat
Finanzdaten der Enanta Pharmaceuticals Inc-Aktie (ENTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):